The 36th Annual Meeting of the Italian Digestive Surgery Society concluded successfully in Rome from November 27 to 28. As one of Europe's largest academic gatherings in digestive surgery, this year's event attracted top surgical experts worldwide, featuring live and recorded surgeries showcasing the latest advancements in gastrointestinal, hepatobiliary, pancreatic, and esophageal procedures. With over 3,000 on-site attendees and 13,000 online participants, the conference has solidified its global influence, having drawn 210,000 online viewers during its 35th edition.
Hengrui Pharma, a leading Chinese pharmaceutical company, partnered with the conference for the second consecutive year, bridging Sino-Italian surgical exchanges. Eleven Chinese surgical teams demonstrated complex procedures across multiple specialties:
1. Academician Dong Jiahong's team (Tsinghua Changgung Hospital) performed ex vivo liver resection with autotransplantation 2. Professor Sun Bei's team (Harbin Medical University) conducted robotic pancreaticoduodenectomy 3. Professor Yu Xianjun's team (Fudan University Cancer Hospital) completed laparoscopic pancreaticoduodenectomy 4. Professor Shen Baiyong's team (Ruijin Hospital) executed robotic pancreaticoduodenectomy for dual lesions 5. Professor Yu Hong's team (Zhejiang University) performed laparoscopic pancreaticoduodenectomy 6. Professor Cheng Wei's team (Hunan Provincial People's Hospital) demonstrated laparoscopic pancreaticoduodenectomy 7. Professor Yu Shi'an's team (Jinhua Central Hospital) conducted laparoscopic pancreaticoduodenectomy 8. Professor Qin Lunxiu's team (Huashan Hospital) performed laparoscopic living donor hepatectomy 9. Professor Chen Gang's team (Wenzhou Medical University) completed laparoscopic duodenectomy 10. Professor Weng Shangen's team (Fujian Medical University) demonstrated laparoscopic pancreaticoduodenectomy 11. Professor Deng Hualiang's team (Shandong University of TCM) performed combined laparoscopic colectomy and hepatectomy
Academician Dong's groundbreaking ex vivo liver resection, described as the "Everest of surgeries," particularly impressed international peers. Professor Giorgio Plazzini, conference president, praised the procedure's textbook execution and team coordination. The surgeries collectively attracted over 5 million online viewers in China.
Hengrui Pharma's commitment to innovation includes: - Cumulative R&D investment exceeding ¥50 billion by Q3 2025 - 7 novel Class 1 drugs approved in 2025 - 13 new drug applications under review - 24 approved Class 1 drugs in China - 100+ innovative products in clinical development - 400+ ongoing clinical trials globally
Through sustained academic collaboration and technological advancement, Hengrui Pharma continues to elevate China's global medical influence while advancing its mission of "Science for Health."
Comments